Inactive Instrument

News Kawasumi Laboratories, Incorporated

Stocks

7703

JP3225800006

Medical Equipment, Supplies & Distribution

All News

20-02-05	Kawasumi Laboratories, Incorporated Reports Consolidated Earnings Results for Nine Months Ended December 31, 2019; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2020	CI
19-11-07	Kawasumi Laboratories, Incorporated Announces Consolidated Earnings Results for the Six Months Ended September 30, 2019; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2020; Announces Dividend for the Second Quarter Ended September 30, 2019, Payable on December 2, 2019; Provides Year End Dividend Guidance for the Year Ending March 31, 2020	CI
19-08-07	Kawasumi Laboratories, Incorporated Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2019; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2020; Provides Dividend Guidance for the Second Quarter of Fiscal 2020 and for the Year Ending March 31, 2020	CI
19-05-15	Sumitomo Bakelite Company Limited completed the acquisition of 20.8% stake in Kawasumi Laboratories, Incorporated.	CI
19-03-19	Sumitomo Bakelite Company Limited executed a capital and business alliance agreement to acquire 20.76% stake in Kawasumi Laboratories, Incorporated.	CI
18-08-09	Tranche Update on Kawasumi Laboratories, Incorporated's Equity Buyback Plan announced on August 9, 2018.	CI
18-08-09	Kawasumi Laboratories, Incorporated's Equity Buyback announced on August 9, 2018 has expired with 1,200,000 shares for ¥860.4 million.	CI
18-08-09	Kawasumi Laboratories, Incorporated announces an Equity Buyback for 1,300,000 shares, representing 5.96% for ¥932.1 million.	CI
18-08-08	Kawasumi Laboratories, Incorporated authorizes a Buyback Plan.	CI
18-05-14	Kawasumi Laboratories, Incorporated Announces Consolidated Earnings Results for the Year Ended March 31, 2018; Announces Dividend for the Year Ended March 31, 2018, Payable on June 22, 2018; Provides Earnings Guidance or the Year Ending March 31, 2019; Provides Dividend Guidance for the Second Quarter and Full Year Ending March 31, 2019	CI
18-02-07	Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the Nine Months Ended December 31, 2017; Provides Earnings and Dividend Guidance for the Year Ending March 31, 2018	CI
17-11-08	Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the Six Months Ended September 30, 2017; Provides Earnings Guidance for the Full Year of Fiscal Year Ending March 31, 2018	CI
17-10-22	Japanese Organization for Medical Device Development, Inc. announced that it has received ¥610 million in funding from Sumitomo Bakelite Company Limited, Kawasumi Laboratories, Incorporated	CI
17-08-08	Kawasumi Laboratories Inc. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2017; Provides Earnings Guidance for the Six Months Ending September 30, 2017 and Full Year Ending March 31, 2018; Provides Second Quarter-End and Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2018	CI
17-05-10	Kawasumi Laboratories, Incorporated Announces Consolidated Earnings Results for the Year Ended March 31, 2017; Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2017 and Full Year Ending March 31, 2018; Announces Dividend for the Year Ended March 31, 2017, Payable on June 23, 2017; Provides Dividend Guidance for the Second Quarter of Fiscal 2018 and for the Year Ending March 31, 2018	CI
17-02-08	Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the nine Months Ended December 31, 2016; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2017; Provides Dividend Guidance for the Year End of Fiscal Year 2017	CI
16-11-09	Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the Six Months Ended September 30, 2016; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2017; Announces Dividend for the Second Quarter End of Fiscal Year 2017, Payable on December 5, 2016; Provides Dividend Guidance for the Year End of Fiscal Year 2017	CI
16-08-09	Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2016; Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2016 and Full Year of Fiscal Year Ending March 31, 2017	CI
16-05-23	Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the Year Ended March 31, 2016; Declares Dividend for the Year Ended March 31, 2016, Payable on June 24, 2016; Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2016 and Full Year Ending March 31, 2017; Provides Dividend Guidance for the Year Ending March 31, 2017	CI
16-02-10	Tranche Update on Kawasumi Laboratories Inc.'s Equity Buyback Plan announced on November 11, 2015.	CI
16-02-09	Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the Third Quarter Ended December 2015	CI
16-02-08	Kawasumi Laboratories Inc.'s Equity Buyback announced on November 11, 2015, has expired with 1,051,400 shares, representing 4.6% for ¥999.95 million.	CI
16-02-02	Tranche Update on Kawasumi Laboratories Inc.'s Equity Buyback Plan announced on November 11, 2015.	CI
15-11-10	Kawasumi Laboratories Inc. authorizes a Buyback Plan.	CI
15-11-10	Kawasumi Laboratories Inc. announces an Equity Buyback for 1,200,000 shares, representing 5.25% for ¥1,000 million.	CI